AUSTIN,
Texas, Jan. 6, 2025 /PRNewswire/ -- Genprex,
Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced that members from its executive leadership team
will be attending and participating in investor, industry and
business development meetings at the 43rd Annual J.P.
Morgan Healthcare Conference, taking place Jan. 13-16, 2025 in San
Francisco, California.
In attendance will be Ryan
Confer, President, Chief Executive Officer and Chief
Financial Officer; Mark Berger, MD,
Chief Medical Officer; and Thomas
Gallagher, Senior Vice President of Intellectual Property
and Licensing. Throughout the duration of the conference, Genprex
executives will be available to conduct one-on-one meetings with
industry and investor groups to provide an overview of the
Company's gene therapies for cancer and diabetes.
For those interested in meeting Genprex management during the
conference, please request a meeting through Investor Relations at
investors@genprex.com.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes. Genprex's technologies are
designed to administer disease-fighting genes to provide new
therapies for large patient populations with cancer and diabetes
who currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. Genprex's oncology program
utilizes its systemic, non-viral Oncoprex® Delivery
System which encapsulates the gene-expressing plasmids using
lipid-based nanoparticles in a lipoplex form. The resultant product
is administered intravenously, where it is taken up by tumor cells
that then express tumor suppressor proteins that were deficient in
the tumor. The Company's lead product candidate,
Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is
being evaluated in two clinical trials as a treatment for NSCLC and
SCLC. Each of Genprex's lung cancer clinical programs has received
a Fast Track Designation from the FDA for the treatment of that
patient population, and Genprex's SCLC program has received an FDA
Orphan Drug Designation. Genprex's diabetes gene therapy approach
is comprised of a novel infusion process that uses an AAV vector to
deliver Pdx1 and MafA genes directly to the pancreas. In models of
Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas
into functional beta-like cells, which can produce insulin but may
be distinct enough from beta cells to evade the body's immune
system. In a similar approach, GPX-002 for Type 2 diabetes, where
autoimmunity is not at play, is believed to rejuvenate and
replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by visiting
the Company Website, registering for Email
Alerts and by following Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are made on the basis of
the current beliefs, expectations and assumptions of management,
are not guarantees of performance and are subject to significant
risks and uncertainty. These forward-looking statements should,
therefore, be considered in light of various important factors,
including those set forth in Genprex's reports that it files from
time to time with the Securities and Exchange Commission and which
you should review, including those statements under "Item 1A – Risk
Factors" in Genprex's Annual Report on Form 10-K for the year ended
December 31, 2023.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
Genprex's ability to advance the clinical development,
manufacturing and commercialization of its product candidates in
accordance with projected timelines and specifications, the timing
and success of Genprex's clinical trials and regulatory approvals,
the effect of Genprex's product candidates, alone and in
combination with other therapies, on cancer and diabetes; the
effects of any strategic research and development prioritization
initiatives, and any other strategic alternatives or other efforts
that Genprex takes or may take in the future that are aimed at
optimizing and re-focusing Genprex's diabetes, oncology and/or
other clinical development programs including prioritization of
resources, and the extent to which Genprex is able to implement
such efforts and initiatives successfully to achieve the desired
and intended results thereof; Genprex's future growth and financial
status, including Genprex's ability to maintain compliance
with the continued listing requirements of The Nasdaq Capital
Market and to continue as a going concern and to obtain capital to
meet its long-term liquidity needs on acceptable terms, or at all;
Genprex's commercial and strategic partnerships, including those
with its third party vendors, suppliers and manufacturers and their
ability to successfully perform and scale up the manufacture of its
product candidates; and Genprex's intellectual property and
licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-to-participate-at-the-43rd-annual-jp-morgan-healthcare-conference-302342275.html
SOURCE Genprex, Inc.
